Cancer Cell
Overview
Cancer Cell is a renowned scientific journal that focuses on cutting-edge research in the field of cancer biology and therapeutics. It publishes high-impact studies that explore the molecular mechanisms underlying cancer development, progression, and treatment resistance. With a multidisciplinary approach, Cancer Cell provides valuable insights into tumor biology, immunotherapy, targeted therapies, and precision medicine, making it an essential resource for cancer researchers and clinicians worldwide.
Details
Details
Abbr.
Cancer Cell
Publisher
Cell Press
Start
2002
End
Continuing
Frequency
Monthly
p-ISSN
1535-6108
e-ISSN
1878-3686
Country
United States
Language
English
Specialty
Oncology
Metrics
Metrics
h-index / Ranks: 74
398
SJR / Ranks: 21
17507
CiteScore / Ranks: 51
52.90
JIF / Ranks: 27
50.3
Recent Articles
1.
Marret G, Herrera M, Siu L
Cancer Cell
. 2025 Mar;
PMID: 40086439
Current clinical trials are based on rigid designs and drug-centric approaches that can stifle flexibility and innovation. With advances in molecular biology and technology, there is an urgent call to...
2.
Zhang Y, Guo Z, Cai X, Rong Z, Fang Y, Chen J, et al.
Cancer Cell
. 2025 Mar;
PMID: 40086438
The abscopal effect of radioimmunotherapy, wherein tumor shrinkage occurs beyond the irradiated field, is therapeutically promising but clinically rare. The mechanisms underlying this effect remain elusive. Here, in vivo genome-wide...
3.
Li H, Zandberg D, Kulkarni A, Chiosea S, Santos P, Isett B, et al.
Cancer Cell
. 2025 Mar;
PMID: 40086437
We leverage a clinical trial (NCT04080804) that compared neoadjuvant anti-PD-1, anti-PD-1+CTLA-4, and anti-PD-1+LAG-3 therapies in head and neck squamous cell carcinoma patients. Combination therapies promote higher pathologic response rates versus...
4.
Mayr L, Neyazi S, Schwark K, Trissal M, Beck A, Labelle J, et al.
Cancer Cell
. 2025 Mar;
PMID: 40086436
PDGFRA is crucial to tumorigenesis and frequently genomically altered in high-grade glioma (HGG). In a comprehensive dataset of pediatric HGG (n = 261), we detect PDGFRA mutations and/or amplifications in...
5.
Wang X, Fang Y, Liang W, Wong C, Qin H, Gao Y, et al.
Cancer Cell
. 2025 Mar;
43(3):564-574.
PMID: 40068601
No abstract available.
6.
Song H, Chen L, Pan X, Shen Y, Ye M, Wang G, et al.
Cancer Cell
. 2025 Mar;
43(3):503-518.e10.
PMID: 40068600
STING is an important DNA sensing machinery in initiating immune response, yet therapies targeting STING have shown poor outcomes in clinical trials. Here, we reveal that STING signaling induces PD-L1...
7.
Pham-Danis C, Novak A, Danis E, McClellan S, Leach L, Yarnell M, et al.
Cancer Cell
. 2025 Mar;
43(3):482-502.e9.
PMID: 40068599
Chimeric antigen receptor (CAR) T cells induce responses in patients with relapsed/refractory leukemia; however, long-term efficacy is frequently limited by relapse. The inability to target antigen-low cells is an intrinsic...
8.
Palmer C, Boras B, Pascual B, Li N, Li D, Garza S, et al.
Cancer Cell
. 2025 Mar;
43(3):464-481.e14.
PMID: 40068598
CDK4/6 inhibitors have revolutionized treatment of hormone receptor positive (HR+), HER2 non-amplified (HER2-) breast cancer. Yet, all "dual" CDK4/6 inhibitors show common dose-limiting hematologic toxicities, foremost neutropenia. This poses challenges...
9.
Yang M, Zhao Y, Li C, Weng X, Li Z, Guo W, et al.
Cancer Cell
. 2025 Mar;
43(3):398-412.e4.
PMID: 40068597
Gallbladder cancer (GBC) frequently mimics gallbladder benign lesions (GBBLs) in radiological images, leading to preoperative misdiagnoses. To address this challenge, we initiated a prospective, multicenter clinical trial (ChicCTR2100049249) and proposed...
10.
Chang J, Lu J, Liu Q, Xiang T, Zhang S, Yi Y, et al.
Cancer Cell
. 2025 Mar;
43(3):380-397.e7.
PMID: 40068596
Cancer development involves the co-evolution of cancer cells and their surrounding microenvironment, yet the dynamics of this interaction within the physical architecture remains poorly understood. Here, we present a spatial...